NRAS mutation

News alerts, weekly reports and conference planners

Entrez ID:

4893

Related biomarkers:

‹

›

Related tests:

Idylla™ ctNRAS-BRAF Mutation Test

NRAS mutation	Melanoma	NRAS mutation	Melanoma	PDR001 + ERAS-254 Sensitive: C3 – Early Trials Eur J Cancer - 1 week (New C3) PDR001 + ERAS-254 Sensitive : C3 Eur J Cancer - 1wk	PDR001 + ERAS-254 Sensitive: C3 – Early Trials Eur J Cancer - 1 week PDR001 + ERAS-254 Sensitive : C3 Eur J Cancer - 1 week - (New C3)
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	cobimetinib + RG6185 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) cobimetinib + RG6185 Sensitive : D ASH 2023 - 4wk	cobimetinib + RG6185 Sensitive: D – Preclinical ASH 2023 - 4 weeks cobimetinib + RG6185 Sensitive : D ASH 2023 - 4 weeks - (New D)
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	RG6185 Sensitive: D – Preclinical ASH 2023 - 4 weeks (New D) RG6185 Sensitive : D ASH 2023 - 4wk	RG6185 Sensitive: D – Preclinical ASH 2023 - 4 weeks RG6185 Sensitive : D ASH 2023 - 4 weeks - (New D)
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2	cetuximab Resistant: A2 - Guideline cetuximab Resistant : A2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
NRAS mutation	Cutaneous Melanoma	NRAS mutation	Cutaneous Melanoma	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2	binimetinib Sensitive: A2 - Guideline binimetinib Sensitive : A2
NRAS mutation	Myelodysplastic Syndrome	NRAS mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B	gilteritinib Resistant: B - Late Trials gilteritinib Resistant : B
NRAS mutation	Thyroid Gland Medullary Carcinoma	NRAS mutation	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B	cabozantinib capsule Sensitive: B - Late Trials cabozantinib capsule Sensitive : B
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	azacitidine Resistant: B - Late Trials azacitidine Resistant : B	azacitidine Resistant: B - Late Trials azacitidine Resistant : B
NRAS mutation	Melanoma	NRAS mutation	Melanoma	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B	KIN-2787 Sensitive: B - Late Trials KIN-2787 Sensitive : B
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	venetoclax Resistant: C2 – Inclusion Criteria venetoclax Resistant : C2	venetoclax Resistant: C2 – Inclusion Criteria venetoclax Resistant : C2
NRAS mutation	Colorectal Cancer	NRAS mutation	Colorectal Cancer	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2	bevacizumab Sensitive: C2 – Inclusion Criteria bevacizumab Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2	ERAS-254 Sensitive: C2 – Inclusion Criteria ERAS-254 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2	FCN-159 Sensitive: C2 – Inclusion Criteria FCN-159 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2	BVD-523 Sensitive: C2 – Inclusion Criteria BVD-523 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2	nivolumab Sensitive: C2 – Inclusion Criteria nivolumab Sensitive : C2
NRAS mutation	Cutaneous Melanoma	NRAS mutation	Cutaneous Melanoma	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2	AS703026 Sensitive: C2 – Inclusion Criteria AS703026 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	RG6185 Resistant: C2 – Inclusion Criteria RG6185 Resistant : C2	RG6185 Resistant: C2 – Inclusion Criteria RG6185 Resistant : C2
NRAS mutation	Thyroid Gland Carcinoma	NRAS mutation	Thyroid Gland Carcinoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
NRAS mutation	Non Small Cell Lung Cancer	NRAS mutation	Non Small Cell Lung Cancer	KO-947 Sensitive: C2 – Inclusion Criteria KO-947 Sensitive : C2	KO-947 Sensitive: C2 – Inclusion Criteria KO-947 Sensitive : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	trametinib + palbociclib Sensitive: C2 – Inclusion Criteria trametinib + palbociclib Sensitive : C2	trametinib + palbociclib Sensitive: C2 – Inclusion Criteria trametinib + palbociclib Sensitive : C2
NRAS mutation	Chronic Myelomonocytic Leukemia	NRAS mutation	Chronic Myelomonocytic Leukemia	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2	lenzilumab Sensitive: C2 – Inclusion Criteria lenzilumab Sensitive : C2
NRAS mutation	Pancreatic Cancer	NRAS mutation	Pancreatic Cancer	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2	avelumab Sensitive: C2 – Inclusion Criteria avelumab Sensitive : C2
NRAS mutation	Solid Tumor	NRAS mutation	Solid Tumor	selumetinib Resistant: C2 – Inclusion Criteria selumetinib Resistant : C2	selumetinib Resistant: C2 – Inclusion Criteria selumetinib Resistant : C2
NRAS mutation	Melanoma	NRAS mutation	Melanoma	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2	HL-085 Sensitive: C2 – Inclusion Criteria HL-085 Sensitive : C2
NRAS mutation	Multiple Myeloma	NRAS mutation	Multiple Myeloma	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3	selinexor Sensitive: C3 – Early Trials selinexor Sensitive : C3
NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	NRAS mutation	Childhood B Acute Lymphoblastic Leukemia	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3	GS-9973 Resistant: C3 – Early Trials GS-9973 Resistant : C3
NRAS mutation	Acute Myelogenous Leukemia	NRAS mutation	Acute Myelogenous Leukemia	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3	cytarabine Resistant: C3 – Early Trials cytarabine Resistant : C3
NRAS mutation	Melanoma	NRAS mutation	Melanoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3

NRAS mutation

Associations